Kumawat Rajani, Nimesh Archana, Jalandra Ramniwas, Agrawal Sandeep, Srinivas H, Ahirwar Ashok K
Department of Biochemistry, All India Institute of Medical Sciences, Bathinda, Punjab, India.
Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bathinda, Punjab, India.
J Family Med Prim Care. 2024 Mar;13(3):1062-1067. doi: 10.4103/jfmpc.jfmpc_1668_23. Epub 2024 Apr 4.
Vaccination has been pivotal in eradicating numerous infectious diseases. Nonetheless, concerns about the safety and side effects of the COVID-19 vaccine persist. This study aimed to gauge the perceptions and experiences of the Indian population concerning COVID-19 vaccination.
This study was a cross-sectional survey of 313 participants aged 18 and above from diverse regions in India. Data was sourced using an electronic questionnaire disseminated via Google Forms. The survey evaluated demographics, vaccine awareness, attitudes, and side effects post-vaccination with Covishield and Covaxin.
22.6% of participants exhibited vaccine hesitancy; however, 78.3% believed the advantages superseded the risks. Most participants (81.5%) were aware of vaccine side effects. Most of the Indian respondents (97.1%) accepted the COVID-19 vaccine. Post-vaccination, 27.9% experienced adverse effects such as fever, headache, malaise, dizziness, and pain at the local site. Only 1.3% necessitated hospitalization.
Our study underscores the dichotomy between vaccine apprehensions and real-world experiences. Although concerns surrounding vaccine safety were prevalent, the majority of the Indian respondents (97.1%) accepted the COVID-19 vaccine, with most experiencing only transient, mild side effects. While 22.6% initially exhibited hesitancy, primarily due to misinformation, the actual experience post-vaccination was largely positive. To further address hesitancy, streamlined vaccine awareness campaigns emphasizing the safety and efficacy of vaccination are essential.
疫苗接种在根除众多传染病方面发挥了关键作用。尽管如此,对新冠疫苗安全性和副作用的担忧依然存在。本研究旨在评估印度人群对新冠疫苗接种的看法和经历。
本研究是一项对来自印度不同地区的313名18岁及以上参与者的横断面调查。数据通过谷歌表单分发的电子问卷收集。该调查评估了人口统计学特征、疫苗知晓情况、态度以及接种Covishield和Covaxin疫苗后的副作用。
22.6%的参与者表现出疫苗犹豫;然而,78.3%的人认为益处大于风险。大多数参与者(81.5%)知晓疫苗副作用。大多数印度受访者(97.1%)接受新冠疫苗。接种疫苗后,27.9%的人出现了诸如发烧、头痛、不适、头晕和局部疼痛等不良反应。只有1.3%的人需要住院治疗。
我们的研究凸显了疫苗担忧与实际接种体验之间的差异。尽管对疫苗安全性的担忧普遍存在,但大多数印度受访者(97.1%)接受了新冠疫苗,大多数人仅经历了短暂、轻微的副作用。虽然22.6%的人最初表现出犹豫,主要是由于错误信息,但接种疫苗后的实际体验总体上是积极的。为了进一步解决疫苗犹豫问题,开展强调疫苗接种安全性和有效性的简化疫苗宣传活动至关重要。